Market Overview

UPDATE: Sterne Agee Resumes Coverage on Covance with Neutral Rating, $76 PT on Current Valuation

Related CVD
Covance Crafts New 52-Week High - Analyst Blog
Morgan Stanley Sees Improving Early Stage for Covance

In a report published Wednesday, Sterne Agee analyst Greg T. Bolan resumed coverage on Covance (NYSE: CVD) with a Neutral rating and $76.00 price target.

In the report, Sterne Agee noted, “CVD possesses the most diversified services portfolio of any CRO, which over the years has insulated the company from heightened volatility in revenue and earnings results. With marked improvement in Central Lab kit volume and mix as well as continued momentum in Clinical results, we think the company will experience accelerating EPS growth. We believe the current valuation reflects our thinking and thus initiate with a Neutral rating and $76 price target.”

Covance closed on Tuesday at $74.91.

Posted-In: Greg T. Bolan Sterne AgeeAnalyst Color Initiation Analyst Ratings

 

Most Popular

Related Articles (CVD)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free